Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722241 · ClinicalTrials.gov registry record
Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System
A clinical trial, sponsored by DexCom.
- Completed
- Registry status
- 53
- Enrollment target
NCT00722241: Completed study, sponsored by DexCom.
NCT00722241 is a clinical trial that has completed, run by DexCom. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00722241 has completed, sponsored by DexCom.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of the next-generation DexCom SEVEN Continuous Glucose Monitoring System (SEVEN.2 System) when worn for up to 7-days by subjects \>18 years-old with diabetes mellitus requiring insulin therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-07 |
What the finished NCT00722241 record still lists
NCT00722241 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 53 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00722241 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00722241 about?
NCT00722241 is a clinical study titled "Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System". The purpose of this study is to evaluate the safety and effectiveness of the next-generation DexCom SEVEN Continuous Glucose Monitoring System (SEVEN.2 System) when worn for up to 7-days by subjects \>18 years-old with diabetes mellitus requiring insulin therapy.
What is the current status of trial NCT00722241?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2008-05. Estimated completion is 2008-07.
Who is sponsoring clinical trial NCT00722241?
This trial is sponsored by DexCom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia